News

A non-small cell lung cancer (NSCLC) patient achieved complete remission (CR) in February 2025 after four months of treatment with SON-DP. A follow-up visit at 14 months reported that the patient maintained continuous complete remission. 

Suzhou Fuent Pharmaceutical Co., Ltd. conducted its Phase I clinical trial in China at Zhongshan Hospital of Fudan University, Peking University Cancer Hospital, Cancer Hospital of Chinese Academy of Medical Sciences, Jiangsu Provincial People’s Hospital, and Zhejiang Cancer Hospital.

The China CDE officially approved the investigational new drug application of Suzhou Fuent Pharmaceutcal Co., Ltd.，and the CDE acceptance number: CXSL2400508.

The 5th SMC meeting held today to discuss the clinical data of the 3 subjects at the dose level of 1.0 mg/kg, Schedule B (twice/week).

Our clinical trial has 4th SMC meeting today to discuss the clinical data of the 3 subjects at the dose level of 2.0 mg/kg, Schedule A (once/week).

Qurgen has successfully GMP manufactured SON-DP, Lot 4 using Qurgen’s own new GMP facility at Qurgen’s subsidiary company: FUENT Pharmaceutics in Suzhou, China.

QURGEN (FUENT) officially engaged with the following 3 sites for Chinese Phase I clinical trial: Zhongshan hospital, Fudan university, Beijing cancer hospital, Beijing University, Jiangsu Renmin province hospital.

Our clinical trial has 3rd SMC meeting today to discuss the clinical data of the 3 subjects at the dose level of 1.0 mg/kg